Suppr超能文献

一种基于黄嘌呤的KMUP-1,在大鼠主动脉平滑肌中具有增强环鸟苷酸及开放钾离子通道的活性。

A xanthine-based KMUP-1 with cyclic GMP enhancing and K(+) channels opening activities in rat aortic smooth muscle.

作者信息

Wu B N, Lin R J, Lin C Y, Shen K P, Chiang L C, Chen I J

机构信息

Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan ROC.

出版信息

Br J Pharmacol. 2001 Sep;134(2):265-74. doi: 10.1038/sj.bjp.0704231.

Abstract
  1. KMUP-1 (1, 3, 5 mg kg(-1), i.v.), a xanthine derivative, produced dose-dependent sustained hypotensive and short-acting bradycardiac effects in anaesthetized rats. This hypotensive effect was inhibited by pretreatment with glibenclamide (5 mg kg(-1), i.v.). 2. In endothelium-intact or denuded aortic rings preconstricted with phenylephrine, KMUP-1 caused a concentration-dependent relaxation. This relaxation was reduced by endothelium removal, the presence of NOS inhibitor L-NAME (100 microM) and sGC inhibitors methylene blue (10 microM) and ODQ (1 microM). 3. The vasorelaxant effects of KMUP-1 was attenuated by pretreatment with various K(+) channel blockers TEA (10 mM), glibenclamide (1 microM), 4-AP (100 microM), apamin (1 microM) and charybdotoxin (ChTX, 0.1 microM). 4. Increased extracellular potassium levels (30 - 80 mM) caused a concentration-related reduction of KMUP-1-induced vasorelaxations. Preincubation with KMUP-1 (1, 10, 100 nM) increased the ACh-induced maximal vasorelaxations mediated by endogenous NO release, and enhanced the potency of exogenous NO-donor SNP. 5. The vasorelaxant responses of KMUP-1 (0.01, 0.05, 0.1 microM) together with a PDE inhibitor IBMX (0.5 microM) had an additive action. Additionally, KMUP-1 (100 microM) affected cyclic GMP metabolism since it inhibited the activity of PDE in human platelets. 6. KMUP-1 induced a dose-related increase in intracellular cyclic GMP levels in rat A10 vascular smooth muscle (VSM) cells, but not cyclic AMP. The increase in cyclic GMP content of KMUP-1 (0.1 - 100 microM) was almost completely abolished in the presence of methylene blue (10 microM), ODQ (10 microM), and L-NAME (100 microM). 7. In conclusion, these results indicate that KMUP-1 possesses the following merits: (1) stimulation of NO/sGC/cyclic GMP pathway and subsequent elevation of cyclic GMP, (2) K(+) channels opening, and (3) inhibition of PDE or cyclic GMP breakdown. Increased cyclic GMP display a prominent role in KMUP-1-induced VSM relaxations.
摘要
  1. 黄嘌呤衍生物KMUP-1(1、3、5毫克/千克,静脉注射)在麻醉大鼠中产生剂量依赖性的持续降压作用和短效的心动过缓作用。这种降压作用可被格列本脲(5毫克/千克,静脉注射)预处理所抑制。2. 在去氧肾上腺素预收缩的完整内皮或去内皮主动脉环中,KMUP-1引起浓度依赖性舒张。去除内皮、存在一氧化氮合酶抑制剂L-NAME(100微摩尔)以及可溶性鸟苷酸环化酶抑制剂亚甲蓝(10微摩尔)和ODQ(1微摩尔)会降低这种舒张作用。3. 用各种钾通道阻滞剂TEA(10毫摩尔)、格列本脲(1微摩尔)、4-氨基吡啶(100微摩尔)、蜂毒明肽(1微摩尔)和蝎毒素(ChTX,0.1微摩尔)预处理可减弱KMUP-1的血管舒张作用。4. 细胞外钾水平升高(30 - 80毫摩尔)导致KMUP-1诱导的血管舒张作用呈浓度相关性降低。用KMUP-1(1、10、100纳摩尔)预孵育可增加由内源性一氧化氮释放介导的乙酰胆碱诱导的最大血管舒张作用,并增强外源性一氧化氮供体硝普钠的效力。5. KMUP-1(0.01、0.05、0.1微摩尔)与磷酸二酯酶抑制剂异丁基甲基黄嘌呤(IBMX,0.5微摩尔)共同作用时,血管舒张反应具有相加作用。此外,KMUP-1(100微摩尔)影响环磷酸鸟苷代谢,因为它抑制人血小板中的磷酸二酯酶活性。6. KMUP-1在大鼠A10血管平滑肌(VSM)细胞中诱导细胞内环磷酸鸟苷水平呈剂量相关增加,但不影响环磷酸腺苷水平。在存在亚甲蓝(10微摩尔)、ODQ(10微摩尔)和L-NAME(100微摩尔)的情况下,KMUP-1(0.1 - 100微摩尔)引起的环磷酸鸟苷含量增加几乎完全被消除。7. 总之,这些结果表明KMUP-1具有以下优点:(1)刺激一氧化氮/可溶性鸟苷酸环化酶/环磷酸鸟苷途径并随后升高环磷酸鸟苷,(2)开放钾通道,以及(3)抑制磷酸二酯酶或环磷酸鸟苷分解。环磷酸鸟苷增加在KMUP-1诱导的血管平滑肌舒张中起重要作用。

相似文献

引用本文的文献

5
Xanthine scaffold: scope and potential in drug development.黄嘌呤骨架:药物研发中的范围与潜力
Heliyon. 2018 Oct 3;4(10):e00829. doi: 10.1016/j.heliyon.2018.e00829. eCollection 2018 Oct.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验